Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: Subanalysis from the JPAD Trial

Hirofumi Soejima(Kumamoto Health Science University), Yoshihiko Saito(National Archives and Records Administration), Hisao Ogawa(Kumamoto University Hospital), Sadanori Okada(Hyogo Medical University), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Masafumi Nakayama(Kumamoto University), Seigo Sugiyama(Diabetes Care Center), Shiro Uemura(Nara Medical University Hospital), Takeshi Morimoto(Hyogo Medical University), Mio Sakuma(Hyogo Medical University), Naofumi Doi(Nara Medical University), Masao Kanauchi(Nara Medical University)
Journal of Cardiology
June 15, 2013
10.1016/j.jjcc.2013.03.015
Cited by 16

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848